Michael S Zastrozhin1,2, Valentin Y Skryabin1, Marco Torrado3, Anastasiya Petrovna1, Alexander S Sorokin1, Elena A Grishina2, Kristina A Ryzhikova2, Inessa A Bedina1, Oleg Z Buzik1, Egor M Chumakov4,5, Ludmila M Savchenko2, Evgeny A Brun1,2, Dmitry A Sychev2. 1. Moscow Research & Practical Centre on Addictions of the Moscow Department of Healthcare, 37/1 Lyublinskaya Street, Moscow 109390, Russian Federation. 2. Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, 2/1 Barrikadnaya Street, Moscow 123995, Russian Federation. 3. University of Lisbon, Faculty of Medicine, ISAMB (Instituto de Saúde Ambiental) venida Professor Egas Moniz (Edifício comum ao Hospital de Santa Maria), 1649-028 Lisboa, Portugal. 4. Saint-Petersburg State University, Department of Psychiatry & Addictions, Saint-Petersburg, Russian Federation. 5. Saint-Petersburg Psychiatric Hospital No. 1 named after PP Kaschenko, Day In-Patient Department, Saint-Petersburg, Russian Federation.
Abstract
Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.
Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.
Authors: M S Zastrozhin; V Yu Skryabin; A E Petukhov; M V Torrado; E P Pankratenko; A K Zastrozhina; E A Grishina; K A Ryzhikova; V V Shipitsyn; E A Bryun; D A Sychev Journal: Pharmacogenomics J Date: 2021-02-19 Impact factor: 3.550